JPRN-UMIN000011661尚未招募2 期
Phase II study of the addition of rituximab to dmCODOX-M/IVAC therapy for AIDS-related burkitt lymphoma - ABL-R trial
ational Hospital Organization Nagoya Medical Center0 个研究点目标入组 26 人开始时间: 2013年9月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Pregnant or possible pregnant women 2. Other active malignancies except for Kaposi sarcoma 3. Severe complication Uncontrollable angina pectoris, myocardial infarction, or heart failure Uncontrollable active infection Uncontrollable diabetes Interstitial pneumonia or pulmonary fibrosis by chest-Xay Uncontrollable opportunistic disease of central nervous system Uncontrollable pleural effusion, ascites or fluid retention in third space Severe psychosis 4. Judged for inappropriate with other reasons
研究者
相似试验
已完成
2 期
Phase II study of rituximab containing induction chemotherapy (R-high-CHOP followed by CHASER) and high-dose chemotherapy (LEED) supported with auto-PBSCT for previously untreated patients with advanced mantle cell lymphoma(JCOG0406)newly diagnosed advanced mantle cell lymphomaJPRN-UMIN000001220Japan Clinical Oncology Group(JCOG)45
已完成
不适用
Phase II study of ramucirumab plus docetaxel plus pegfilgrastim with stage IV non-small cell lung cancer patientsnon-small cell lung cancerJPRN-UMIN000025972Gunma University20
招募中
2 期
A pilot study of combining rituximab and low-dose (1.0Gy) total nodal irradiation in treatment of extensive chronic graft-versus-host diseaseChronic graft-versus-host disease (GVHD)Blood - Haematological diseasesACTRN12607000628448Simon He and Andrew Grigg20
进行中（未招募）
2 期
Phase II study of ramucirumab in combination with erlotinib for untreated EGFR mutation-positive non-squamous non-small cell lung cancer patients with pleural effusion: RELAY-EffusioEGFR mutation positive advanced non-small cell lung cancerJPRN-jRCTs051210138Kaneda Hiroyasu40
已完成
2 期
A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07)Diffuse large B-cell lymphomaJPRN-UMIN000001050Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)40